
Clinical trials of a preventative vaccine for the Ebola virus made by British pharma company GlaxoSmithKline may begin next month and made available by 2015, the World Health Organization said on Saturday.
"We are targeting September for the start of clinical trials, first in the United States and certainly in African countries, since that's where we have the cases," Jean-Marie Okwo Bele, the WHO's head of vaccines and immunisation, told French radio.
He said he was optimistic about making the vaccine commercially available. "We think that if we start in September, we could already have results by the end of the year.
"And since this is an emergency, we can put emergency procedures in place ... so that we can have a vaccine available by 2015."
There is currently no available cure or vaccine for Ebola, a virus that causes severe fever and, in the worst cases, unstoppable bleeding.
It has claimed close to 1,000 lives in the latest epidemic to spread across west Africa this year. Fatality rates can approach 90 percent, although the latest outbreak has killed around 55 to 60 percent of those infected.
Several vaccines are being tested, and a treatment made by San Diego-based Mapp Biopharmaceutical, ZMapp, has shown promising results on monkeys and may have been effective in treating two Americans recently infected in Africa.
GMT 18:35 2018 Thursday ,11 January
Syrian refugee sets himself ablaze at UN office in LebanonGMT 18:48 2018 Tuesday ,09 January
Novo Nordisk woos Belgian nano-drug makerGMT 17:54 2017 Wednesday ,27 December
Medical evacuations begin from besieged Syria rebel bastionGMT 12:14 2017 Monday ,25 December
MoHAP successfully conducts cochlear implant operationGMT 18:24 2017 Sunday ,24 December
Palestinian conjoined twins arrive in RiyadhGMT 19:05 2017 Monday ,18 December
new! magazine names fitness & food editorGMT 17:03 2017 Wednesday ,29 November
Spain reports case of 'mad cow disease'GMT 14:05 2017 Saturday ,11 November
EU can't agree on new licence for controversial glyphosate weedkiller
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor